X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ALEMBIC PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA ALEMBIC PHARMA AUROBINDO PHARMA/
ALEMBIC PHARMA
 
P/E (TTM) x 17.0 16.7 102.0% View Chart
P/BV x 3.4 4.5 75.4% View Chart
Dividend Yield % 0.4 0.8 48.9%  

Financials

 AUROBINDO PHARMA   ALEMBIC PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
ALEMBIC PHARMA
Mar-18
AUROBINDO PHARMA/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs809645 125.4%   
Low Rs504470 107.3%   
Sales per share (Unadj.) Rs281.1166.1 169.2%  
Earnings per share (Unadj.) Rs41.421.9 188.9%  
Cash flow per share (Unadj.) Rs50.927.5 185.1%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.40.7 53.1%  
Book value per share (Unadj.) Rs199.4117.8 169.3%  
Shares outstanding (eoy) m585.88188.52 310.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.4 69.6%   
Avg P/E ratio x15.925.5 62.4%  
P/CF ratio (eoy) x12.920.3 63.6%  
Price / Book Value ratio x3.34.7 69.6%  
Dividend payout %6.018.3 33.1%   
Avg Mkt Cap Rs m384,630105,090 366.0%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3086,228 342.1%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66631,308 526.0%  
Other income Rs m1,02070 1,450.6%   
Total revenues Rs m165,68631,378 528.0%   
Gross profit Rs m37,7186,431 586.5%  
Depreciation Rs m5,5801,055 529.1%   
Interest Rs m77734 2,285.9%   
Profit before tax Rs m32,3805,413 598.2%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-81 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,1831,204 679.9%   
Profit after tax Rs m24,2294,128 586.9%  
Gross profit margin %22.920.5 111.5%  
Effective tax rate %25.322.2 113.7%   
Net profit margin %14.713.2 111.6%  
BALANCE SHEET DATA
Current assets Rs m121,87818,247 667.9%   
Current liabilities Rs m86,80611,235 772.6%   
Net working cap to sales %21.322.4 95.1%  
Current ratio x1.41.6 86.4%  
Inventory Days Days13086 151.8%  
Debtors Days Days6861 111.4%  
Net fixed assets Rs m81,03720,035 404.5%   
Share capital Rs m586377 155.4%   
"Free" reserves Rs m116,21821,824 532.5%   
Net worth Rs m116,80422,201 526.1%   
Long term debt Rs m4,5125,000 90.2%   
Total assets Rs m211,05239,411 535.5%  
Interest coverage x42.7160.2 26.6%   
Debt to equity ratio x00.2 17.2%  
Sales to assets ratio x0.80.8 98.2%   
Return on assets %11.810.6 112.2%  
Return on equity %20.718.6 111.6%  
Return on capital %27.419.7 138.7%  
Exports to sales %046.4 0.0%   
Imports to sales %010.5 0.0%   
Exports (fob) Rs mNA14,535 0.0%   
Imports (cif) Rs mNA3,288 0.0%   
Fx inflow Rs m80,72714,722 548.4%   
Fx outflow Rs m34,7007,026 493.9%   
Net fx Rs m46,0277,696 598.1%   
CASH FLOW
From Operations Rs m19,5483,124 625.7%  
From Investments Rs m-19,570-8,844 221.3%  
From Financial Activity Rs m8,6425,026 171.9%  
Net Cashflow Rs m8,922-693 -1,286.9%  

Share Holding

Indian Promoters % 54.1 74.1 73.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 2.9 274.1%  
FIIs % 27.7 9.1 304.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 13.9 73.4%  
Shareholders   69,601 49,328 141.1%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT  SUVEN LIFESCIENCES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Dip After Record Rally; Sensex Ends 298 Points Lower(Closing)

It was a volatile day for Indian share markets today. The BSE Sensex and NSE Nifty opened at record high and went on to touch 40,000 and 12,000.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 23, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS